Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGRONOMICS LIMITED Net Asset Value 2013

Jan 25, 2013

7474_rns_2013-01-25_26a685cd-cc41-4452-a119-526071f923f7.html

Net Asset Value

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4243W

Port Erin Biopharma Investments Ltd

25 January 2013

Port Erin Biopharma Investments Limited ("the Company")

Net Asset Value calculation to 31st December 2012

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2012 was 9.50 pence per share, including un-invested cash of £101,241. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a small decrease from the previous valuation of 9.63 pence per share, which included un-invested cash of £329,708. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and still represents a return of over 16.0% on investments after operating costs. Indeed, if the NAV valuation were to be published today, the NAV per share would approach 10.4 pence."

Unaudited

15 September 2011

to 31 December 2012

£
Fixed Assets
Investments 3,031,135
Current Assets
Debtors: amounts owing 9,035
Un-invested cash 101,241
Current Liabilities
Creditors: amounts due (7,292)
3,134,119
Capital and Reserves
Share Capital 33
Share Premium 2,699,011
Capital reserve - realised 0
Capital reserve - unrealised 0
Revenue reserve 435,075
3,134,119
Shares in Issue 33,000,000
Net Asset Value per share 9.50 pence

--- ENDS ---

Portfolio Details

Investments Schedule at 31st December 2012 Valuation £ Portfolio %
Summit Corporation plc £269,166.87 8.88%
Cytox Limited £200,000.00 6.60%
Gilead Sciences Inc. £195,452.13 6.45%
Synergy Pharmaceuticals Inc. £182,814.82 6.03%
Plethora Solutions Holdings plc £180,000.00 5.94%
Celgene Inc. £141,125.68 4.66%
Astellas Pharma Inc. £140,762.00 4.64%
Arrowhead Resources £135,419.97 4.47%
TrovaGene Inc. £127,845.13 4.22%
Abbott Laboratories £117,762.25 3.89%
Pfizer Inc. £114,835.48 3.79%
£1,805,184.33 59.55%
Aggregate value of remaining holdings below 3% of total portfolio £1,225,950.25 40.45%
TOTAL INVESTMENTS £3,031,134.58 100.00%

For further information, please contact:

Port Erin Biopharma Investments Ltd Libertas Capital Corporate Finance Limited Peterhouse Capital Limited
The Company Nomad Broker
Denham Eke

+44 162 463 9396
Sandy Jamieson

+44 207 569 9650
Jon Levinson

+44 207 562 3350

This information is provided by RNS

The company news service from the London Stock Exchange

END

NAVLLFFELRIEFIV